165 related articles for article (PubMed ID: 31419601)
21. Osteogenesis Imperfecta: Muscle-Bone Interactions when Bi-directionally Compromised.
Phillips CL; Jeong Y
Curr Osteoporos Rep; 2018 Aug; 16(4):478-489. PubMed ID: 29909596
[TBL] [Abstract][Full Text] [Related]
22. Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Liu M; Hammers DW; Barton ER; Sweeney HL
PLoS One; 2016; 11(11):e0166803. PubMed ID: 27870893
[TBL] [Abstract][Full Text] [Related]
23. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
[TBL] [Abstract][Full Text] [Related]
24. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta.
Grafe I; Yang T; Alexander S; Homan EP; Lietman C; Jiang MM; Bertin T; Munivez E; Chen Y; Dawson B; Ishikawa Y; Weis MA; Sampath TK; Ambrose C; Eyre D; Bächinger HP; Lee B
Nat Med; 2014 Jun; 20(6):670-5. PubMed ID: 24793237
[TBL] [Abstract][Full Text] [Related]
25. A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I.
Liu Y; Wang J; Liu S; Kuang M; Jing Y; Zhao Y; Wang Z; Li G
Bone; 2019 Oct; 127():646-655. PubMed ID: 31369917
[TBL] [Abstract][Full Text] [Related]
26. Craniofacial and Dental Defects in the Col1a1Jrt/+ Mouse Model of Osteogenesis Imperfecta.
Eimar H; Tamimi F; Retrouvey JM; Rauch F; Aubin JE; McKee MD
J Dent Res; 2016 Jul; 95(7):761-8. PubMed ID: 26951553
[TBL] [Abstract][Full Text] [Related]
27. Metabolic phenotype in the mouse model of osteogenesis imperfecta.
Boraschi-Diaz I; Tauer JT; El-Rifai O; Guillemette D; Lefebvre G; Rauch F; Ferron M; Komarova SV
J Endocrinol; 2017 Sep; 234(3):279-289. PubMed ID: 28716975
[TBL] [Abstract][Full Text] [Related]
28. Regulation of body mass growth through activin type IIB receptor in teleost fish.
Carpio Y; Acosta J; Morales R; Santisteban Y; Sanchéz A; Estrada MP
Gen Comp Endocrinol; 2009 Jan; 160(2):158-67. PubMed ID: 19056390
[TBL] [Abstract][Full Text] [Related]
29. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
30. Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta.
Forlino A; Tani C; Rossi A; Lupi A; Campari E; Gualeni B; Bianchi L; Armini A; Cetta G; Bini L; Marini JC
Proteomics; 2007 Jun; 7(11):1877-91. PubMed ID: 17520686
[TBL] [Abstract][Full Text] [Related]
31. Muscle-bone properties after prolonged voluntary wheel running in a mouse model of dominant severe osteogenesis imperfecta.
Tauer JT; Rigo Canevazzi GH; Schiettekatte-Maltais J; Rauch F; Bergeron R; Veilleux LN
J Musculoskelet Neuronal Interact; 2021 Dec; 21(4):517-527. PubMed ID: 34854391
[TBL] [Abstract][Full Text] [Related]
32. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
33. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
[TBL] [Abstract][Full Text] [Related]
34. Calvaria Bone Transcriptome in Mouse Models of Osteogenesis Imperfecta.
Moffatt P; Boraschi-Diaz I; Marulanda J; Bardai G; Rauch F
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069814
[TBL] [Abstract][Full Text] [Related]
35. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.
Jacobsen CM; Barber LA; Ayturk UM; Roberts HJ; Deal LE; Schwartz MA; Weis M; Eyre D; Zurakowski D; Robling AG; Warman ML
J Bone Miner Res; 2014 Oct; 29(10):2297-306. PubMed ID: 24677211
[TBL] [Abstract][Full Text] [Related]
36. Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass.
Goh BC; Singhal V; Herrera AJ; Tomlinson RE; Kim S; Faugere MC; Germain-Lee EL; Clemens TL; Lee SJ; DiGirolamo DJ
J Biol Chem; 2017 Aug; 292(33):13809-13822. PubMed ID: 28659341
[TBL] [Abstract][Full Text] [Related]
37. Hindlimb Skeletal Muscle Function and Skeletal Quality and Strength in +/G610C Mice With and Without Weight-Bearing Exercise.
Jeong Y; Carleton SM; Gentry BA; Yao X; Ferreira JA; Salamango DJ; Weis M; Oestreich AK; Williams AM; McCray MG; Eyre DR; Brown M; Wang Y; Phillips CL
J Bone Miner Res; 2015 Oct; 30(10):1874-86. PubMed ID: 25829218
[TBL] [Abstract][Full Text] [Related]
38. Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
Boraschi-Diaz I; Chen G; Polak-Nachumow J; Young RN; Rauch F
Bone; 2021 Apr; 145():115867. PubMed ID: 33524637
[TBL] [Abstract][Full Text] [Related]
39. OIM and related animal models of osteogenesis imperfecta.
Shapiro JR; Mcbride DJ; Fedarko NS
Connect Tissue Res; 1995; 31(4):265-8. PubMed ID: 15612365
[TBL] [Abstract][Full Text] [Related]
40. Exploration of the skeletal phenotype of the
Claeys L; Zhytnik L; Wisse LE; van Essen HW; Eekhoff EMW; Pals G; Bravenboer N; Micha D
Front Endocrinol (Lausanne); 2023; 14():1145125. PubMed ID: 36967771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
